HempNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Approaching Commercialization of IGC-AD1 in Early 2018

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization… Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.” The newly-announced results, when combined with earlier reported data showing that IGC-AD1 reduces Aβ production and inhibits Aβ aggregation without any neuronal toxicity, represent a novel breakthrough toward the treatment of Alzheimer’s, which is known as America’s most expensive disease with an estimated annual cost to the U.S. economy of $236 billion.

To view the full press release, visit http://cnw.fm/Jd717

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

More from CannabisNewsBreaks

• HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 
• HempNewsBreaks – WEED Inc. (BUDZ) Announces 2024 Highlights, Plans to Expand into Consumer Packaged Goods
• HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net